Syndax Pharmaceuticals.
business
- Reports this week
- 0
- Active events
- 0
- Connections
- 42
What's happening
Earlier this month
-
Syndax Pharmaceuticals reported collaboration revenue derived from Niktimvo sales.Well supported6 reports
-
Syndax Pharmaceuticals confirms Michael Metzger as CEO and Botwood as Chief Medical Officer.Some support3 reports
-
Syndax Pharmaceuticals has FDA-approved therapies in its pipeline and uses LinkedIn for company communication.Some support8 reports1 development inside
-
Syndax Pharmaceuticals received an award from the Galien Foundation on October 30, 2026.Some support1 report
-
Syndax Pharmaceuticals management attended conferences in Boston, London, and New York on October 30, 2026.Some support1 report
-
Syndax Pharmaceuticals presented data at EHA Congress and is seeking successful regulatory approval for its drug pipeline.Some support2 reports
-
Analysts set price targets for Syndax Pharmaceuticals stock on September 1, 2025.Well supported3 reports
One to three months ago
-
Shares of Syndax Pharmaceuticals were traded on the Nasdaq stock exchange on August 12, 2026.Some support3 reports1 development inside
-
Syndax Pharmaceuticals' share price dropped following a clinical trial failure.Some support1 report
-
Syndax Pharmaceuticals and AbbVie are competing in the healthcare and biopharma sector.Some support2 reports
Gone quiet
No new reports in 90+ days-
CEO Michael Metzger sold shares of Syndax Pharmaceuticals stock.Some support1 report
-
Trump's pledge to unleash oil and gas benefits US stocks, specifically impacting Syndax Pharmaceuticals.Some support1 report
-
On June 25, 2025, the FDA approved revumenib for acute leukemia, and data was presented at the EHA Congress in Milan.Speculative1 report1 development inside
-
FDA granted Priority Review for Syndax's sNDA on June 25, 2025.Speculative2 reports
-
Syndax Pharmaceuticals' stock price moved following changes in earnings estimates, prompting institutional investors to calculate fair value.Some support1 report
-
FDA approval of Revuforj is key catalyst for Syndax Pharmaceuticals.Some support3 reports
No events began in the chosen period. Widen it, or reset.
Around Syndax Pharmaceuticals this week
News at the entities that move Syndax Pharmaceuticals most-
FDA StructuralFDA issued a warning letter to NeoGen regarding a product quality defect on October 7, 2026.Moves Syndax Pharmaceuticals
-
Bank of America OperationalBank of America issued a report warning of limited EPS upside and downgraded a stock from Buy to Neutral.Moves Syndax Pharmaceuticals
-
Nasdaq StructuralAnthropic, developer of Claude Code, is seeking a listing on the Nasdaq Global Select Market.Moves Syndax Pharmaceuticals
-
AbbVie OperationalDHS leans on AbbVie, Altria, and Merck for stock weighting, while the SEC legally requires fiduciaries to prioritize client interests.Moves Syndax Pharmaceuticals
-
Stockholm Shared contextMunters held a Capital Markets Day in Stockholm on November 11, 2026.Moves Syndax Pharmaceuticals
-
Milan Shared contextA world tour is currently spanning multiple international markets, including Bangkok and Milan.Moves Syndax Pharmaceuticals
Connections
The 20 strongest of 42, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Incyte Operational
Syndax and Incyte maintain an exclusive worldwide co-development and co-commercialization partnership for the drug Niktimvo.
-
FDA Structural
The FDA formally regulates Syndax Pharmaceuticals, reviewing and approving its therapeutic pipeline.
-
Aaron Structural
Syndax Pharmaceuticals formally appointed Aaron as CFO, establishing a structural employment relationship where he leads financial strategy.
-
Botwood Structural
Botwood serves as the chief medical officer for Syndax Pharmaceuticals.
-
Michael Metzger Structural
Michael Metzger serves as the Chief Executive Officer of Syndax Pharmaceuticals.
-
Nasdaq Structural
Syndax Pharmaceuticals is a publicly listed company whose shares are traded on the Nasdaq stock exchange.
-
Closter Structural
Closter holds the role of Chief Commercial Officer at Syndax Pharmaceuticals.
-
Metzger Structural
Metzger serves as the Chief Executive Officer of Syndax Pharmaceuticals.
Show all 20 connections
-
AbbVie Operational
The two companies are actively competing against each other within the specialized healthcare and biopharma market.
-
Bank of America Operational
Bank of America provides market assessments and commentary regarding the stock performance of Syndax Pharmaceuticals.
-
LinkedIn Mentioned together
Syndax Pharmaceuticals utilizes LinkedIn as a professional platform to disseminate company news and updates.
-
Stockholm Shared context
Syndax Pharmaceuticals is located in Stockholm, where it presented data at EHA Congress.
-
Milan Shared context
Syndax Pharmaceuticals presents scientific data at the EHA Congress held in Milan.
-
Galen Transactional
Syndax Pharmaceuticals received an award from Galen (or associated entity) in 2026.
-
MarketBeat Mentioned together
MarketBeat provides analyst ratings and financial information regarding Syndax Pharmaceuticals.
-
New York Shared context
Syndax Pharmaceuticals operates within the geographical context of New York.
-
New York Shared context
Syndax Pharmaceuticals operates within the context of New York, a major market backdrop.
-
Italy Shared context
Syndax Pharmaceuticals operates within the geographical context of Italy for scientific congresses.
-
New York City Shared context
Syndax Pharmaceuticals is reported to be operating within the context of New York City.
-
Boston Shared context
Syndax Pharmaceuticals is noted as attending a conference held in Boston.
History
Events by the month they beganOctober 2026
3 eventsSeptember 2026
1 eventAugust 2026
1 eventShow 2 earlier months
July 2026
2 eventsJune 2026
9 events- Syndax Pharmaceuticals reported collaboration revenue derived from Niktimvo sales.
- Syndax Pharmaceuticals has FDA-approved therapies in its pipeline and uses LinkedIn for company communication.
- Syndax Pharmaceuticals presented data at EHA Congress and is seeking successful regulatory approval for its drug pipeline.
- Analysts set price targets for Syndax Pharmaceuticals stock on September 1, 2025.
- Trump's pledge to unleash oil and gas benefits US stocks, specifically impacting Syndax Pharmaceuticals.
- On June 25, 2025, the FDA approved revumenib for acute leukemia, and data was presented at the EHA Congress in Milan.
- FDA granted Priority Review for Syndax's sNDA on June 25, 2025.
- Syndax Pharmaceuticals' stock price moved following changes in earnings estimates, prompting institutional investors to calculate fair value.
- FDA approval of Revuforj is key catalyst for Syndax Pharmaceuticals.